EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) explained in plain language.
Never miss a new study
Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) trials appear
Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for EGPA: rituximab shows promise in major trial
Disease control CompletedThis study tested whether the drug rituximab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) achieve remission better than standard treatments. 107 adults with active EGPA were randomly assigned to receive either rituximab or conven…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a tiny dose of naltrexone ease vasculitis symptoms?
Symptom relief CompletedThis study tested whether a low dose (4.5 mg) of naltrexone, a drug already used for alcoholism, can improve physical health and quality of life in people with vasculitis. Sixty participants took either the drug or a placebo daily for six weeks. The goal was to see if the drug le…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Massive study reveals hidden dangers of common steroid treatments
Knowledge-focused CompletedThis completed study looked at over 107,000 patients in Germany to understand the long-term side effects of systemic steroids (corticosteroids) used for conditions like asthma, COPD, and arthritis. Researchers compared patients who took steroids with those who did not, tracking r…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC